These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 15618294)

  • 1. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
    Wehkamp J; Schmid M; Fellermann K; Stange EF
    J Leukoc Biol; 2005 Apr; 77(4):460-5. PubMed ID: 15618294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
    Wehkamp J; Stange EF
    Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease.
    Simms LA; Doecke JD; Walsh MD; Huang N; Fowler EV; Radford-Smith GL
    Gut; 2008 Jul; 57(7):903-10. PubMed ID: 18305068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defensin-immunology in inflammatory bowel disease.
    Wehkamp J; Stange EF; Fellermann K
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
    Ramasundara M; Leach ST; Lemberg DA; Day AS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
    Wehkamp J; Harder J; Weichenthal M; Schwab M; Schäffeler E; Schlee M; Herrlinger KR; Stallmach A; Noack F; Fritz P; Schröder JM; Bevins CL; Fellermann K; Stange EF
    Gut; 2004 Nov; 53(11):1658-64. PubMed ID: 15479689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
    Peyrin-Biroulet L; Chamaillard M
    J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defensins and other antimicrobial peptides in inflammatory bowel disease.
    Wehkamp J; Schmid M; Stange EF
    Curr Opin Gastroenterol; 2007 Jul; 23(4):370-8. PubMed ID: 17545771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease.
    Wang G; Stange EF; Wehkamp J
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1049-57. PubMed ID: 18039087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human defensins in Crohn's disease.
    Wehkamp J; Fellermann K; Stange EF
    Chem Immunol Allergy; 2005; 86():42-54. PubMed ID: 15976487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.
    Kübler I; Koslowski MJ; Gersemann M; Fellermann K; Beisner J; Becker S; Rothfuss K; Herrlinger KR; Stange EF; Wehkamp J
    Aliment Pharmacol Ther; 2009 Sep; 30(6):621-33. PubMed ID: 19549264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues.
    Wehkamp J; Chu H; Shen B; Feathers RW; Kays RJ; Lee SK; Bevins CL
    FEBS Lett; 2006 Oct; 580(22):5344-50. PubMed ID: 16989824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
    Strober W; Asano N; Fuss I; Kitani A; Watanabe T
    Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOD2 mutation and mice: no Crohn's disease but many lessons to learn.
    Wehkamp J; Stange EF
    Trends Mol Med; 2005 Jul; 11(7):307-9. PubMed ID: 15955743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of defensins in the pathogenesis of chronic-inflammatory bowel disease].
    Schmid M; Fellermann K; Wehkamp J; Herrlinger K; Stange EF
    Z Gastroenterol; 2004 Apr; 42(4):333-8. PubMed ID: 15095125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Barrier- and autophagic functions of the intestinal epithelia: role of disturbances in the pathogenesis of Crohn's disease].
    Lapis K
    Orv Hetil; 2010 Oct; 151(40):1645-55. PubMed ID: 20860961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease.
    Wehkamp J; Koslowski M; Wang G; Stange EF
    Mucosal Immunol; 2008 Nov; 1 Suppl 1():S67-74. PubMed ID: 19079235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population.
    Bianchi V; Maconi G; Ardizzone S; Colombo E; Ferrara E; Russo A; Tenchini ML; Porro GB
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):217-23. PubMed ID: 17301648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterisation of decoy receptor 3 in Crohn's disease.
    Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
    Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease.
    D'Incà R; Annese V; di Leo V; Latiano A; Quaino V; Abazia C; Vettorato MG; Sturniolo GC
    Aliment Pharmacol Ther; 2006 May; 23(10):1455-61. PubMed ID: 16669960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.